|By PR Newswire||
|September 27, 2012 12:25 PM EDT||
LUBBOCK, Texas, Sept. 27, 2012 /PRNewswire/ -- Positron Corporation (OTCBB:POSC), a molecular imaging healthcare company will be presenting at the 1st International Business Conference for Producers, Suppliers and Consumers of Isotope Products (1IBCI), which will take place in Moscow, Russia, October 1st - 3rd, 2012.
The 1IBCI conference, organized by Isotope Co., an entity within the Rosatom State Atomic Energy Corporation's (ROSATOM) Program "Radiation Technologies," will focus on the business and scientific issues, plans and perspectives of the world isotope industry. The conference will be attended by the scientific community made up of key isotope market players and experts from various countries that will discuss the latest trends, global isotope consumption & market development, isotope production & supply, applications, products and devices in the industry. The conference is expected to give a new impetus to the international cooperation in the sphere of isotope applications and will facilitate the entire industry entering a qualitatively new level of development.
ROSATOM incorporates a vast number of scientific institutions in the world market of nuclear technologies. ROSATOM links manufacturers and consumers of isotope products in both domestic and foreign markets.
Jason Kitten, President of Manhattan Isotope Technology a subsidiary of Positron Corporation, was invited to speak on the topic of Nuclear Medicine Trends. "This conference is key in connecting and collaborating with the strategic global isotope players and enables Positron to establish itself and our business opportunities on a world stage with most all of the leading isotope producing organizations."
About Positron: Positron Corporation is a molecular imaging healthcare company vertically integrating all the segments of nuclear cardiology—providing an end-to-end solution for cardiac PET. Through proprietary PET imaging systems, radiopharmaceuticals and radioisotopes, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron's unique products, market position and approach in securing the supply chain are substantial advantages, further accelerating the adoption of cardiac PET and growth of nuclear cardiology. Positron is redefining the industry. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
SOURCE Positron Corporation